This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

15 Feb 2012

Ockham Completes Acquisition of Nexus Oncology

This merger offers an enhanced global scale, a depth of oncology-specific therapeutic expertise and new levels of operational excellence.

US-based CRO Ockham announced yesterday that it has completed the acquisition of clinical research services provider Nexus Oncology. The transaction also provides Ockham with an institutional investment partner.


The combined company will operate under the name Ockham and will be led by Ockham’s Chief Executive Officer, James V. Baker, and a joint Ockham and Nexus management team. 


Nexus Oncology will be known as Nexus Oncology, an Ockham company. Clare Wareing, founder of Nexus, will continue with the new organization serving as Chief Scientific Officer.  In addition, the company’s board of directors will have representatives from both the existing Ockham and Nexus boards.

Related News